(A) general formula (i)< Conversion 1 >So the 1 thio D glucitol compound which is displayed and, (B) the biguanaido medicine, the insulin secretion promotion medicine and the insulin sensitivity reinforcement medicine, the insulin, from the jipepuchijirupepuchidaze IV inhibiter, the gurukoshidaze inhibiter and the group which consists of the GLP 1 operation medicine 1 kinds or more which are chosen,As for the medicine which becomes combining, diabetes, the diabetes-related disease or the preventive curative effect of the diabetes complication are superior, at the same time, cannot see the side effect.< Selective figure >It is not(A)一般式(I)【化1】で表される1-チオ-D-グルシトール化合物と、(B)ビグアナイド薬、インスリン分泌促進薬、インスリン感受性増強薬、インスリン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤およびGLP-1作動薬からなる群より選ばれる1種以上、を組み合わせてなる医薬は、糖尿病、糖尿病関連疾患または糖尿病合併症の予防・治療効果が優れ、かつ、副作用が見られない。【選択図】なし
